Paediatric rheumatology: Biologic therapy for systemic juvenile idiopathic arthritis-times they are a'changing!

Nature Reviews Rheumatology

Volumn 9, Issue 2, 2013, Pages 63-

  Buckland, Jenny ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TOCILIZUMAB;

BIOLOGICAL THERAPY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; NEUTROPENIA; NOTE; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 84873406177     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.2     Document Type: Note

References (2)

1. De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2385-2395 (2012)
2. Ruperto, N. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367, 2396-2406 (2012)